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N-Methyl-D-Aspartate Receptor 







• Stands for “N-Methyl-D-Aspartate 
Receptor”, which a is a synaptic 
receptor believed to be present in 
>90% of synaptic junctions
• However, the receptor accepts 
glutamate (a key excitatory 
neurotransmitter) and glycine as 
its ligands
• Activating the NMDA receptor 
leads to an inhibitory effect
NMDAR Immunity
• Despite its necessity, antibodies that downregulate the receptor can 
be developed, leading to higher levels of brain stimulation and 
excitement
• The body can present subunits for the protein (such as NR1) as 
antigens and thus develop specific immunity to the protein
• This effect is particularly common in the case of HSV infection, as 
observed by Dr. Pruss et al’s research team
HSV – Herpes Simplex Virus
• Inflammatory response tends not to arise from the brain
• However, infection can occur when viral and bacterial 
antigens infiltrate the blood-brain barrier (especially prions)
• Microglia (phagocytes within the central nervous system) 
are typically responsible for eliminating antigens in the CNS, 
but their relative number is low
• Furthermore, HSV-1 (the variant used within the study) has 
been shown to be particularly infectious
• ”[In 2016], an estimated 3752.0 million people had HSV type 1 
infection at any site, equivalent to a global prevalence of 66.6% in 
0-49 year olds” (James et al.)”
HSE – Herpes Simplex Encephalitis
• Despite the prevalence of HSV type 1, the encephalitis form is quite uncommon 
as it requires the centralization of the virus within the brain as opposed to more 
susceptible areas such as the eyes and nose (1 in 500,000 persons per year)
• The infection leads to an inflammatory response within the brain, leading to the 
accumulation of CSF (cerebral spinal fluid) and serum around the infected area
• In comparison with other infections that transmit themselves throughout the 
body, the brain blood supply is relatively isolated in the brain
HSE - Herpes Simplex Encephalitis
• Due to the lack of immune support within the 
brain, the symptoms of HSE remain for extended 
periods of time
• What is encephalitis?
• The inflammatory response induced by the viral 
infection
• The inflammation leads to swelling, causing the brain 
to press against the meninges and skull
• Patients with encephalitis usually complain of 
headache, mild-flu like symptoms, and neck stiffness
What is used to treat HSE?
• Acyclovir, an antiviral, is commonly prescribed to treat HSV1
• Pharmacy names: Sitavig, Zovirax
A secondary immune response?
• It was observed that HSE patients who were immunocompetent had 
more severe symptoms that patients who were immunocompromised
• In essence, the younger individuals tended to be worse off than older 
patients with HSE
• This finding suggests the presence of a secondary immune response –
an immune response targeted at something that is NOT the virus (an 
autoimmune response)
• This hypothesis is in line with improved outcomes “when combining 
acyclovir with corticosteroids”
• Corticosteroids suppress an immune response
Immunity against NMDAR
• When you add immunity against NMDAR, neurons are attacked 
because of two mechanisms as opposed to one: 
• 1. viral cytotoxicity 
• 2. detection of NMDA surface receptor (become the target of a specific 
immune response)
• HSE usually develops in the hippocampus, leading to cognitive 
(memory) and limbic (behavioral, emotional) deficits
• These symptoms are easily detected by family members, but they are 
difficult to identify on the part of the patients
• “Interestingly, we detected significantly longer intervals between the first 
prodromal symptoms and hospital admission in patients with NMDAR 
antibodies.”
Experimental Methods
• “we performed a blinded retrospective study analyzing a large 
archived cohort of consecutive serum and cerebrospinal fluid (CSF) 
samples from patients with a definite diagnosis of HSE”
• The identities of the patients were masked from the experimenters
• The experimenters extracted only the CSF and serum of these patients, as 
these locations are where you can observe an immune response (test for 
antibody concentration, median white blood cell count, protein 
concentration)
• All 44 patients studied were diagnosed with HSE as proved by PCR techniques
• Going forward: HSE ≠ anti-NMDAR encephalitis
Patients
• All patients had presented three common characteristics: 
• Diagnosed with HSE in accordance with the German Society of 
Neurology standards
• Had laboratory and imaging findings
• Received IV acyclovir treatments for at least 2 weeks
• Control patients (“Entero”)
• 10 patients with enterovirus encephalitis
• 10 patients with varicella zoster virus
• Both of these viruses are related to herpes simplex virus
• Informed consent was taken retrospectively
Testing for Antibodies
• Method: recombinant immunofluorescence
• Plasmids encoding for NMDAR were introduced to 
HEK293 cells (human embryonic kidney cells) and 
these cells were grown on slides
• Fragments from the slides were cut and put 
alongside rat hippocampus and cerebellum cells
• Finally, these samples were introduced to CSF and 
serum samples from the patients and incubated at 
room temperature
Testing for Antibodies
• After incubation, the samples 
were treated with fluorescein-
conjugated goat-anti-human IgG, 
IgA, or IgM antibodies for 30 min 
• These antibodies, independent of 
the antibodies from the patient 
serum or CSF, would target the 
NMDARs
• The samples were then washed 
with PBS
Testing for Antibodies
• The prevalence of antibodies could be 
determined based on the illumination of 
the antibody stains
• If the stains were sufficiently bright, the 
patient was considered immuno-positive 
toward anti-NMDAR antibodies
• When the antibody for NMDAR index was 
>4 for an Ig class prior to dilution, there 
was evidence of NMDAR-specific 
immunity for that Ig class (immuno-
positive result)
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Testing for Antibodies – Results
• A: Immunity to NMDA receptors observed for IgM
• B + C: No immunity to NMDA receptors observed for IgA and IgG
• D - F: In IgM immunopositively samples, the stains from recombinant immunofluorescence from the patient 
antibodies and the goat antibodies are shown individually, as well as merged
Obtaining mouse hippocampus cultures
• Cells from the mouse hippocampus were first obtain from a lab
• Cells were then applied to a growth solution (“fetal calf serum”, ...)
• Cells were then spun in a centrifuge
• Cells were then resuspended (mixed in, usually after centrifugation), into another serum containing a mix of 
chemicals usually present within the cellular space of neurons
Western Blot of Mouse Hippocampus Cells
Sample 
Preparation
•At day 10, neurons were 
isolated and resuspended 
in cytotoxic factors, and 
spun in a centrifuge. 
Gel 
Electrophoresis
•Remaining solution was 
added to  a stacking gel, 
and a current was applied 
causing the proteins to 
separate based on 




•The separating gel is placed 
between membranes that 
acquire the proteins and 
enable antibody detection 
through placement in an 
electric field. Membrane was 




from a protein 
cocktail




• Antibodies specific to the 
protein, protein subunit, 
or peptide of interest (in 
this case, the NR1 subunit) 
is introduced to the 
membrane in such a way 




• The antibodies are brought 
to illuminate. Based on the 
intensity of the light, the 
density of the protein can be 
assessed. The presence of 
luminescence also means 




from a protein 
cocktail
Western Blot of Mouse Hippocampus Cells –
Results
• Actin (control): no observed downregulation as no antibodies against actin were created as they had HSE
• NMDAR – NR1 subunit: In the patient serum, the presence of the NR1 subunit of NMDAR is lower than when 
no patient serum or CSF was added
• Thus, the patient antibodies lead to deterioration of NMDAR
Immunocytochemistry 
• The researchers are also able to quantify the downregulation of 
NMDARs by staining the plates and comparing the presence of 
NMDAR for plates treated with patient serum/CSF and compare it to 
a control
• Anti-synapsin antibody was used for staining (does not downregulate 
NMDAR on its own – is just a staining technique)
• After three days of exposure to the patient serum, the fluorescence of 
each sample was observed
• However, without converting to grayscale, a complex image is derived 
and cannot be assessed quantitatively
Immunocytochemistry – Results
• On day 1, the presence of the red dots would be virtually the same
• However, after three days, the red dots have reduced in number, suggested a decline in the amount of NMDAR 
due to the presence of anti-NMDAR antibodies in the patient serum/CSF
• In grayscale, the brightness of the surrounding anti-synapsin antibodies is significantly lower in the patient 
serum, suggesting once again that NMDAR antibodies was downregulated
General Results
• In 13/44 patients, an immuno-positive result was 
observed 




• Recombinant immunofluorescence confirmed the 
presence of NMDAR antibodies
• Furthermore, the Western Blot and 
immunocytochemistry procedures quantified the 
downregulation (decline) in the amount of NMDAR 
present in the mouse hippocampus cells after being 
exposed to the patient serum
General Results
• In 2 of the patients, they demonstrated immunity against both the 
NR1 and NR2 subunits of NMDAR
• Antibodies against cancer or other diseases were not detected, 
suggesting a strong correlation between HSE and the development of 
the anti-NMDAR antibodies
• Even when the researchers lowered the initial concentrations of the 
CSF and serum, 11/44 tests com out as immuno-positive (25%) and 
lead to the downregulation of NMDAR
• IgM wasfound to downregulate NMDAR at a similar level to IgA and 
IgG (novel insight)
General Results
• In some patients, antibody titers for NMDAR were found in days 4-9 
after diagnosis, suggesting that antibodies against NMDAR did not 
come about because of infection with HSV
• Hypothesis: HSE symptoms were difficult to detect, and the antibodies began 
to develop after the onset of HSV instead of the point of diagnosis
• However, when treated with acyclovir, clinical symptoms reduced, 
and immunity toward NMDAR dropped
• After clinically presenting with HSE, patients largely experienced the 
same symptoms at the same intensities whether they were immuno-
positive to NMDAR or not
General Results
• The presence of NMDAR antibodies did not lead to poorer 
symptoms?
• The downregulation of NMDAR did not lead to worse cognition or pain
• Undermines the usefulness of NMDAR in the nervous system
• However, being antibody-positive toward NMDAR did lead to a delay 
for clinical presentation
• However, the “clinical course of patients was not different”
• Downregulation of NMDAR was only observed in patients with IgG 
antibodies
Novel Insights
• IgG led to the worst effects in terms of 
the downregulation of NMDAR despite 
only playing an autoimmune role in 4/44 
patients
• However, IgM also caused loss of NMDAR 
from the cell-membrane and a lower 
expression of synapsin (a general marker 
for synaptic receptors), similar to the 
previously-observed effects of IgG against 
NMDAR in other studies
• Thus, immunoglobulin of all classes play a 
role in NMDA-related encephalitis
Conclusions
• At a rate of at least 25%, NDMAR antibodies were present in patients 
presenting with HSE and led to the downregulation of NMDAR
• Thus, physicians must way the potential effects of HSE on a macroscale 
(pressure from the skull) as well as a microlevel (lower expression of 
synaptic proteins)
• So, infection with HSV leading to encephalitis leads to autoimmunity to 
NMDAR
• How?
• Perhaps those 25% of HSE patients are presenting with anti-NMDAR encephalitis
• Unlikely, given the low prevalence of both disease
• There must be a causal factor
Conclusions
• Hypothesis: After cell lysis due to viral destruction, 
cellular membranes are presented to immune cells in 
the brain as antigens, leading to an autoimmune 
response
• Another hypothesis: The CNS inflammation in HSE 
patients caused an immune response and led to the 
identification of multiple antigens for a specific immune 
response, leading to the crossover between HSE and 
anti-NMDAR encephalitis
• Discussion Question: Which hypothesis serves as a 
more reliable reason for the autoimmune response to 
NMDAR?
Further Conclusions
• Despite the lack of more complicated clinical symptoms until the end 
of HSE treatment, NMDAR immunity does not bode well long-term
• Has been linked to choreoathetosis in patients (jerky moments due to lack of 
inhibition in neurons) 1 month into treatment
• However, this finding may be a side effect of acyclovir
• Following treatment, seizures arise
• No long-term follow-up was conducted, preventing the study of 
continued NMDAR immunity
Clinical Implications
• Patients with HSE should be tested for NMDAR immunity 
• Long-term follow-ups with patients immuno-positive for NMDAR after 
coming out of HSE should be conducted
• Additional screening on patients with IgA and IgM antibodies should 
be conducted since these antibodies were more frequent than IgG 
antibodies
• Patients with HSE and anti-NMDAR encephalitis may benefit from 
immunotherapy (ex: acyclovir)
Discussion Questions
• Should anti-NMDAR immunity treatments be a 
concern for researchers given the prevalence of other 
life-changing disorders such as diabetes and cancer?
• Would you expect HSV-1 immunity due to a vaccine 
to lead to lower levels of anti-NMDAR immunity?
• Technological tools allowed the researchers to 
observe the staining of the neurons at a cellular level 
and convert the synapsin-stained slides into grayscale 
images. Should we place a greater emphasis on 
technology instead of fundamental research?
• The antibody index of 4 is arbitrary (unless 
established from previous research). Should we rely 
on more quantitative means for research instead of 
trying to visualize the data qualitatively (ex: by using 
staining techniques)?
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